内容紹介
A Questionnaire Survey on QOL and Toxicity in Colorectal Cancer Survivors Who Received Adjuvant Chemotherapy
Summary
The relative risk of cancer recurrence with postoperative adjuvant FOLFOX/CapeOX therapy(Ox)for stageⅢ colorectal cancer is reduced by approximately 20% when compared to that with fluorouracil plus Leucovorin. We performed a questionnaire survey to evaluate the quality of life(QOL)and extent of side effects in patients who received adjuvant chemotherapy. In order to evaluate the risks and benefits of oxaliplatin administration, we also examined the differences in awareness of oxaliplatin side effects between patients and medical staff. Responses were obtained from 147 patients, 54 doctors, and 84 nurses. Analysis of the patient responses showed higher current QOL scores regardless of the chemotherapy regimen, although patients in the Ox group had a high rate of residual sensory peripheral neuropathy. In the Ox group, 81% of patients responded that the side effects were moderate. In contrast, 40% of medical staff identified the side effects of oxaliplatin as severe, which differed from that reported by the patients. Considering that Ox adjuvant chemotherapy may reduce the risk of recurrence by approximately 20%, the risk/benefit balance is acceptable.
要旨
大腸癌術後補助化学療法を受けた患者147人,化学療法に携わる医師54人,看護師84人を対象にしたアンケート調査を行った。結果,オキサリプラチン併用(Ox)療法を受けた患者は,フッ化ピリミジン単独(Non-Ox)療法を受けた患者と比較して末梢性感覚ニューロパチーのスコアが高い傾向にあったが,健康関連QOLスコアは両群とも良好であった。また,治療中の副作用についてOx療法を受けた患者の81%が治療の副作用は中等度であったと回答した。一方,医療者の約40%はOx療法の副作用を強いと思うと回答し,実際に治療を受けた患者と医療者との間でOx療法へのイメージに乖離が認められた。Ox併用による相対的再発リスク低下の上乗せを勘案すると,StageⅢ大腸癌術後補助化学療法においてOx療法のリスクベネフィットバランスは許容できると考えられた。
目次
Summary
The relative risk of cancer recurrence with postoperative adjuvant FOLFOX/CapeOX therapy(Ox)for stageⅢ colorectal cancer is reduced by approximately 20% when compared to that with fluorouracil plus Leucovorin. We performed a questionnaire survey to evaluate the quality of life(QOL)and extent of side effects in patients who received adjuvant chemotherapy. In order to evaluate the risks and benefits of oxaliplatin administration, we also examined the differences in awareness of oxaliplatin side effects between patients and medical staff. Responses were obtained from 147 patients, 54 doctors, and 84 nurses. Analysis of the patient responses showed higher current QOL scores regardless of the chemotherapy regimen, although patients in the Ox group had a high rate of residual sensory peripheral neuropathy. In the Ox group, 81% of patients responded that the side effects were moderate. In contrast, 40% of medical staff identified the side effects of oxaliplatin as severe, which differed from that reported by the patients. Considering that Ox adjuvant chemotherapy may reduce the risk of recurrence by approximately 20%, the risk/benefit balance is acceptable.
要旨
大腸癌術後補助化学療法を受けた患者147人,化学療法に携わる医師54人,看護師84人を対象にしたアンケート調査を行った。結果,オキサリプラチン併用(Ox)療法を受けた患者は,フッ化ピリミジン単独(Non-Ox)療法を受けた患者と比較して末梢性感覚ニューロパチーのスコアが高い傾向にあったが,健康関連QOLスコアは両群とも良好であった。また,治療中の副作用についてOx療法を受けた患者の81%が治療の副作用は中等度であったと回答した。一方,医療者の約40%はOx療法の副作用を強いと思うと回答し,実際に治療を受けた患者と医療者との間でOx療法へのイメージに乖離が認められた。Ox併用による相対的再発リスク低下の上乗せを勘案すると,StageⅢ大腸癌術後補助化学療法においてOx療法のリスクベネフィットバランスは許容できると考えられた。